induced pluripotent stem cells

[AgeX Therapeutics, Inc.] AgeX Therapeutics, Inc. announced that ImStem Biotechnology, Inc., a biopharmaceutical company developing human ESC-derived mesenchymal stem cells, has dosed the first US multiple sclerosis patient with ImStem’s lead investigational drug candidate IMS001.

[eLife] Investigators reported a rapid protocol for the derivation of the human ATOH1 lineage, the precursor of excitatory cerebellar neurons, from human pluripotent stem cells.

[Cell Research] Guided by insights from a large-scale single-cell transcriptome analysis of pig embryos from embryonic day (E) 0 to E14, the authors developed an in vitro culture medium for establishing and maintaining stable PSC lines from pig E10 pregastrulation epiblasts.

[Cell Reports] Scientists reported that the metabolic landscape of human PSCs was shifted by signaling lipid lysophosphatidic acid (LPA), which naturally exists. LPA led to a distinctive transcriptome profile that was not associated with de novo lipogenesis.

[Molecular Therapy-Methods & Clinical Development] Investigators found that the editing efficiency of cytosine base editor was significantly lower than that of adenine base editor in human ESCs, which were associated with high expression of DNA glycosylases, the key component of the base excision repair pathway.

[Cell Stem Cell] A functional dataset allowed improving mesoderm induction by ROCK inhibition, contained monogenetic and complex trait kidney disease genes, confirmed two additional congenital anomalies of the kidney and urinary tract genes, and provided a large candidate list of ciliopathy-related genes.